StockData

Addex Therapeutics vs Kazia Therapeutics

ADXN and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADXN and KZIA compare

Addex Therapeutics grew revenue faster over the last twelve months (−92.6% versus −98.2% for Kazia Therapeutics).

Kazia Therapeutics scores higher on the StockData Score (1 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADXNKZIA
Size and price
Share price$3.50$5.31
Change, 1 year−58.7%−15.3%
Change, 5 years−97.5%−98.9%
Beta (5Y)1.954.08
Employees314
StockData Score
Total score01 (better)
Valuation score00
Growth score00
Performance score00
Health score01 (better)
Dividend score00
Growth
Revenue growth (TTM)−92.6% (better)−98.2%
Revenue growth, 5Y average−61.6%–
EPS growth (TTM)−186%–
Profitability
Operating margin−9391%–
Net margin–−49291%
FCF margin−7244%–
Financial health
Interest coverage−181.0×–
Current ratio0.762.87 (better)
Piotroski F-score–2
Ownership
Held by institutions0.00%0.45%
Held by insiders15.5%0.29%
Superinvestors holding–1

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.